<a href="https://www.fiercebiotech.com/biotech/incyte-inks-2b-deal-add-star-unit-late-phase-constellation-and-challenge-takeda" hreflang="en">Incyte inks $2B deal to add Star unit to late-phase constellation and challenge Takeda</a>
Incyte has announced a $2 billion deal to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, to enhance its hematology portfolio with a late-phase drug candidate for von Willebrand disease (VWD). The acquisition aims to bolster Incyte's growth as it faces patent expiration challenges for its existing drug, Jakafi, by potentially offering a new standard of care for VWD patients.
The key insight for someone interested in healthtech and biotech investments is that Incyte's acquisition of Vega Therapeutics, a Star Therapeutics subsidiary, presents a strategic move to enter the bleeding disorder market with VGA039, a promising phase 3 monoclonal antibody candidate. This acquisition positions Incyte to potentially capture a significant share of the von Willebrand disease market, challenging Takeda's Vonvendi and aiming for approximately $1 billion in net sales post-2029, marking it as a significant growth driver as Jakafi faces patent expiration.